Investor interest in artificial intelligence-powered drug discovery shows little signs of wearing off, as start-up Genesis Therapeutics rakes in an impressive $200 million in an oversubscribed ...

Incyte and Genesis Therapeutics have entered a strategic partnership aimed at the research, discovery and development of new small-molecule medicines. Incyte will choose the initial collaboration ...

“Many drug targets are novel, and they have very little or no known chemical matter that modulates them,” says Evan Feinberg, founder and CEO of Genesis Therapeutics. To cope with the paucity ...

Additionally, Incyte has entered a strategic collaboration with Genesis Therapeutics to utilize AI for discovering new small molecule drugs, with potential milestone payments up to $295 million per ...

As someone deeply immersed in the field of cell therapy, it thrills me to witness the rapid advancements that are pushing the boundaries of patient care further and faster than ever before.

BridGene is eligible to receive $770 million in milestone payments. And, U.S.-based Genesis Therapeutics and Incyte have signed a $30 million licensing agreement to develop small molecules. Genesis ...

NEUCHATEL, Switzerland (AP) — The world’s woes got you down? Feeling burnout at work? Need a little something extra to fight ...

The Swiss town of Neuchatel is offering residents a novel form of preventative or preparatory medicine: museum visits as art ...